Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + Sorafenib + Tislelizumab for Advanced HCC
NCT04599777Phase 2Completed
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Oct 2020
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Started Oct 2020; status: completed.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04599777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04599777.